n-methyladenosine has been researched along with Cancer of Prostate in 11 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 11 (100.00) | 2.80 |
Authors | Studies |
---|---|
Cai, C; Duan, X; Liang, Y; Lin, Z; Liu, Q; Liu, Z; Lu, J; Sun, X; Wu, W; Zeng, G; Zeng, J; Zhong, J; Zhong, W | 1 |
Feng, Y; Mi, Y; Wan, H; Wu, J; Zhu, L | 1 |
Han, M; Liu, J; Song, Y; Wang, C; Wang, Y; Yan, F | 1 |
Deng, Y; Lin, H; Liu, Y; Luo, L; Wang, J; Xiang, Q; Zhao, Z; Zhou, M; Zhu, Z | 1 |
Du, C; Feng, Y; Lv, C; Yu, S | 1 |
Chen, H; He, L; Li, J; Liang, Z; Liu, B; Wang, X; Xie, H; Xie, L; Xu, M; Xu, X; Yan, H; Ying, Y; Zheng, X | 1 |
Niu, Y; Wei, Y; Wen, S; Xiong, W; Zen, C; Zhao, Y | 1 |
Liu, JH; Ou-Yang, S; Wang, QZ | 1 |
Li, Y; Xu, Y; Zhu, K | 1 |
Dai, Y; Du, H; Lang, C; Li, Y; Lin, K; Peng, X; Ren, D; Wu, Z; Yang, Q; Yin, C | 1 |
Chen, P; Chen, Y; Han, X; Hu, J; Ma, Y; Pan, C; Rao, Q; Wang, X; Xiang, Z; Xu, D | 1 |
1 review(s) available for n-methyladenosine and Cancer of Prostate
Article | Year |
---|---|
Functions and mechanisms of N6‑methyladenosine in prostate cancer (Review).
Topics: Adenosine; Epigenesis, Genetic; Humans; Male; Prostatic Neoplasms | 2022 |
10 other study(ies) available for n-methyladenosine and Cancer of Prostate
Article | Year |
---|---|
Characterization of the m6A-Associated Tumor Immune Microenvironment in Prostate Cancer to Aid Immunotherapy.
Topics: Adenosine; Biomarkers, Tumor; Clinical Decision-Making; Databases, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heterogeneous-Nuclear Ribonucleoprotein Group A-B; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Lymphocytes, Tumor-Infiltrating; Male; Methyltransferases; Nuclear Proteins; Prostatic Neoplasms; RNA Processing, Post-Transcriptional; RNA-Binding Proteins; T-Lymphocytes, Helper-Inducer; Transcriptome; Tumor Microenvironment; Tumor-Associated Macrophages | 2021 |
Cyclodextrin-Functionalized Gold Nanorods Loaded with Meclofenamic Acid for Improving
Topics: Adenosine; Cell Line, Tumor; Cyclodextrins; Gold; Humans; Immunotherapy; Male; Meclofenamic Acid; Nanotubes; Phototherapy; Prostatic Neoplasms; RNA; Tumor Microenvironment | 2022 |
The m6A methylation regulator-based signature for predicting the prognosis of prostate cancer.
Topics: Adenosine; Cluster Analysis; Computational Biology; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Methylation; Prognosis; Proportional Hazards Models; Prostatic Neoplasms; RNA, Messenger; ROC Curve; Transcriptome | 2020 |
Activation of the KDM5A/miRNA-495/YTHDF2/m6A-MOB3B axis facilitates prostate cancer progression.
Topics: Adenosine; Animals; Apoptosis; Biomarkers, Tumor; Cell Movement; Cell Proliferation; Disease Progression; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Microtubule-Associated Proteins; Prognosis; Prostatic Neoplasms; Retinoblastoma-Binding Protein 2; RNA-Binding Proteins; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
Topics: Adenosine; Animals; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Male; Methyltransferases; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Prognosis; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; RNA Stability; RNA-Binding Proteins; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Long non-coding RNA NEAT1 promotes bone metastasis of prostate cancer through N6-methyladenosine.
Topics: Adenosine; Aged; Aged, 80 and over; Animals; Bone Neoplasms; Cell Line, Tumor; Core Binding Factor Alpha 1 Subunit; Cyclin-Dependent Kinases; Cyclins; Humans; Male; Mice, Nude; Middle Aged; Phosphorylation; Phosphoserine; Prognosis; Promoter Regions, Genetic; Prostatic Neoplasms; RNA Polymerase II; RNA, Long Noncoding | 2020 |
Expression patterns and a prognostic model of m
Topics: Adenocarcinoma; Adenosine; Aged; Biomarkers, Tumor; Gene Expression Profiling; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Proteins; Prognosis; Prostatic Neoplasms; Risk Assessment | 2020 |
The FTO m
Topics: Adenosine; Aged; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Biomarkers, Tumor; Carcinogenesis; Cell Line, Tumor; Cell Movement; Humans; Male; Middle Aged; Neoplasm Invasiveness; Prostate; Prostatic Neoplasms | 2021 |
m
Topics: Adenosine; Animals; Apoptosis; Biomarkers, Tumor; Bone Neoplasms; Cell Cycle; Cell Movement; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Prognosis; Prostatic Neoplasms; Receptor, IGF Type 1; RNA Stability; RNA-Binding Proteins; RNA, Long Noncoding; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Silencing of METTL3 effectively hinders invasion and metastasis of prostate cancer cells.
Topics: Adenosine; Cell Movement; Cell Proliferation; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Male; Methyltransferases; Neoplasm Invasiveness; Neoplasm Metastasis; Prostate; Prostatic Neoplasms; RNA-Binding Proteins; RNA, Messenger; Ubiquitin-Specific Proteases | 2021 |